UroGene S.A. Acquires Exclusive Exclusive Development And Commercialization Rights For Besipiridine Rights From Aventis Pharmaceuticals, Inc. (AVE)
10/19/2005 5:09:38 PM
UroGene S.A. announced today that they company have has signed an exclusive development and commercialization agreement with Aventis Pharmaceuticals, Inc. for Besipirdine, thato UroGene for furtherwill develop for the clinical development intreatment of Over Active Bladder (OAB).
Besipirdine has been formerly developedwas previously under evaluation by Aventis up to phase III up to Phase III clinical trials for Alzheimer’s disease, involving the administration of the compound to over 1500 patients and. UroGene recently has demonstrated the potential for the compound in OAB as a new C-fiber inhibitor with an original mechanism of action. UroGene will pursue development starting from phase II clinical trials in OAB patients.
comments powered by